Synthesis method of polypeptide fragments in ZP8396 polypeptide compound
The synthesis steps of Petrelintide peptide fragments were optimized by liquid-phase synthesis, solving problems such as N-methylated amino acid coupling and selective cyclization of lactam bridges. This enabled efficient and low-cost production of peptide fragments, improved purity and synthesis efficiency, and supported large-scale preparation.
Patent Information
- Application Number
- CN202611430423.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to efficiently synthesize peptide fragments in Petrelintide (ZP8396), particularly in the areas of N-methylated amino acid coupling, selective cyclization of lactam bridges, and precise introduction of fatty acid side chains. This results in low synthesis efficiency and low purity, making it difficult to meet the requirements of industrial production.
A liquid-phase synthesis method was employed, involving specific condensation, deprotection, coupling, and cyclization reaction steps, using specific catalysts and solvents, and optimizing reaction conditions, including the selection of suitable condensing agents, deprotecting agents, catalysts, and solvents, to ensure the efficient synthesis of key fragments in Petrelintide.
This method enables the efficient synthesis of key Petrelintide fragments, improves peptide purity and synthesis efficiency, reduces waste emissions, lowers purification difficulty, and supports large-scale production.
Smart Images

Figure CN123106874A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of liquid phase synthesis technology, and more specifically, to a method for synthesizing polypeptide fragments in the ZP8396 polypeptide compound. Background Technology
[0002] Obesity and type 2 diabetes have become global metabolic diseases, creating an urgent clinical need for novel metabolic regulators that are long-acting, highly tolerable, and combine weight loss with glycemic regulation. Amylin, a satiety-regulating hormone co-secreted with insulin, has receptors that, along with calcitonin receptors, constitute important energy metabolism regulatory targets. Its pathways complement those of existing incretin drugs, making it a valuable candidate for clinical development.
[0003] Petrelintide (development code ZP8396) is a next-generation long-acting amylin analog developed by Zealand Pharma. It is a 36-amino acid acylated peptide and is currently in Phase II clinical trials for the treatment of obesity and type 2 diabetes. This molecule acts through a dual agonist mechanism of action targeting both the amylin and calcitonin receptors (DACRA). In animal models and early clinical studies, it has demonstrated significant weight loss effects and good gastrointestinal tolerability, and is compatible with existing GLP-1 inhibitors. The synergistic effect of this type of therapy represents an important innovative direction for drugs treating metabolic diseases. To achieve long-lasting efficacy and physicochemical stability, the molecule underwent targeted structural optimization, introducing a lactam bridge-constrained conformation and N... Methylated amino acids improve metabolic stability and solubility, and albumin binding is achieved through fatty acid side chain acylation to prolong half-life, supporting once-weekly subcutaneous administration.
[0004] However, the unique structure of Petrelintide presents significant challenges in its chemical synthesis. Its poor natural molecular stability and complex synthetic routes have become key bottlenecks restricting its commercial production and quality control. The core difficulties in its synthetic process lie in: N... Methylated amino acids are difficult to couple due to steric hindrance and low reactivity; lactam bridges at specific sites within the sequence require highly selective cyclization to avoid mismatches and side reactions; and fatty acid side chains need to be precisely and quantitatively introduced to ensure long-lasting effects and uniformity. Particularly noteworthy is the presence of methylated amino acids at sequence 25. Position 28 is a notoriously difficult sequence in solid-phase peptide synthesis (SPPS). Due to steric hindrance, interchain aggregation, and reaction kinetics, it has low coupling efficiency under conventional condensation conditions and is prone to racemic and deletion peptide side reactions, which significantly reduce the purity and overall yield of the crude product and make it difficult to meet the requirements of industrial scale-up and pharmaceutical consistency.
[0005] Currently, existing peptide synthesis technologies still lack efficient, highly selective, and scalable synthetic strategies for challenging sequences containing multiple unnatural modifications, conformational constraints, and lipidation modifications. Furthermore, mature methods for coupling, cyclization, and modification of key fragments have not yet been publicly disclosed. Therefore, developing an efficient solid-phase synthesis process suitable for Petrelintide, and overcoming the challenges posed by N... Methylated amino acid coupling, selective cyclization of lactam bridges, precise introduction of fatty acid side chains, and sequence 25 Overcoming core technical challenges such as the synthesis of the 28-position difficult fragment is of great significance for achieving stable, low-cost, and large-scale preparation of this molecule. It can also provide a reference technical paradigm for the process development of similar long-acting peptide drugs with complex structures and high synthesis difficulty.
[0006] In view of this, the present invention is proposed. Summary of the Invention
[0007] The purpose of this invention is to provide a method for synthesizing polypeptide fragments in the ZP8396 polypeptide compound. The synthesis method provided in this invention not only solves problems such as low coupling efficiency and easy racemization, but also makes it possible to reduce synthesis steps and emissions of waste in solid-phase polypeptide synthesis, and can also improve polypeptide purity and reduce purification difficulty.
[0008] This invention is implemented as follows: In a first aspect, the present invention provides a method for synthesizing polypeptide fragments in a ZP8396 polypeptide compound, comprising: S1: condensing RN-Me-Ile-OH and Leu-OR1 salt to form RN-Me-Ile-Leu-OR1; S2: Remove R from RN-Me-Ile-Leu-OR1 to form HN-Me-Ile-Leu-OR1; S3: Fmoc-Ala-OH is condensed with HN-Me-Ile-Leu-OR1 to form Fmoc-Ala-N-Me-Ile-Leu-OR1; S4: Remove R1 from Fmoc-Ala-N-Me-Ile-Leu-OR1 to form Fmoc-Ala-N-Me-Ile-Leu-OH; S5; Fmoc-Ala-N-Me-Ile-Leu-OH is coupled with H-Ser-OR1 salt to form Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1; S6: Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 undergoes a ring-closing reaction under the catalysis of a catalyst to form Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1; S7: Remove R1 from Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 to form Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OH; Where R is any one of Fmoc, Boc, Cbz, and Alloc, and R1 is any one of Bn, Me, Et, tBu, OMB, and PMB.
[0009] In an optional implementation, R stands for Fmoc and R1 stands for Bn.
[0010] In an optional embodiment, S1: The RN-Me-Ile-OH, the Leu-OR1 hydrochloride, the condensing agent, and the base are mixed and reacted; Preferably, the reaction conditions of S1 satisfy at least one of the following requirements: (1) The molar ratio of RN-Me-Ile-OH to Leu-OR1 hydrochloride is 1:(1.1-1.3). (2) The condensing agent is selected from at least one of HOBT, TBTU and HATU; (3) The ratio of RN-Me-Ile-OH to the condensing agent is 1:(2-2.5); (4) The ratio of RN-Me-Ile-OH to the base is 1:(2-2.5); (5) The base includes a nitrogen-containing organic compound, preferably N-methylimidazole; (6) The reaction temperature is 0-5℃ and the reaction time is 2-6h.
[0011] In an optional embodiment, S2: RN-Me-Ile-Leu-OR1, the deprotecting agent, and the solvent are mixed to remove R; Preferably, the reaction conditions for S2 satisfy at least one of the following requirements: (1) The reaction temperature is 0-10℃; (2) The deprotecting agent includes a bicyclic amidine organic strong base, preferably DBU; (3) The solvent includes furan derivatives or amides, preferably DMF or THF; (4) The molar ratio of RN-Me-Ile-Leu-OR1 to the deprotecting agent is 1: (0.8-1.2).
[0012] In an optional embodiment, S3: Fmoc-Ala-OH, the HN-Me-Ile-Leu-OR1, the condensing agent and the solvent are mixed and reacted; Preferably, the reaction conditions for S3 satisfy at least one of the following requirements: (1) The molar ratio of Fmoc-Ala-OH and HN-Me-Ile-Leu-OR1 is 1:(1-1.5). (2) The condensing agent includes EEDQ or PyAOP; The solvent includes furan derivatives or amide substances, preferably DMF or THF; (3) The reaction temperature is 0-5℃ and the reaction time is 2-30h.
[0013] In an optional implementation, S4: hydrogenation to remove R1 from Fmoc-Ala-N-Me-Ile-Leu-OR1; Preferably, palladium carbon hydrogenation is used to remove R1 from the Fmoc-Ala-N-Me-Ile-Leu-OR1; Preferably, the reaction conditions for S4 satisfy at least one of the following requirements: (1) The mass ratio of Fmoc-Ala-N-Me-Ile-Leu-OR1 to palladium on carbon is (8-12):1; (2) The reaction temperature is 10-20℃; (3) The solvents used for hydrogenation removal include furan solvents or ester solvents, preferably tetrahydrofuran or ethyl acetate.
[0014] In an optional embodiment, S5: The solvent, Fmoc-Ala-N-Me-Ile-Leu-OH and condensing agent are mixed at -5 to 0°C. After mixing, the mixture is stirred at 10-20°C, and then cooled to -5 to 0°C. Organic acid is added, followed by H-Ser-OR1 hydrochloride, solvent and amine. The mixture is then reacted at 10-20°C. Preferably, the reaction conditions of S5 satisfy at least one of the following requirements: (1) The molar ratio of the Fmoc-Ala-N-Me-Ile-Leu-OH salt to the H-Ser-OR1 salt is 1:(1.1-1.3); (2) The condensing agent includes at least one of HOSU, DIC, EDCI and TBTU; (3) The amines include DIEA.
[0015] In an optional embodiment, S6: Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 is formed by cyclization reaction of 2-methoxypropylene under the catalysis of PPTS.
[0016] In an optional embodiment, S6: the solvent, Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 and PPTS are mixed, and then 2-methoxypropylene is added in batches under an inert gas atmosphere; Preferably, (1) the molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 to PPTS is 1:(0.08-0.12). (2) The molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 to 2-methoxypropylene is 1:(6-12). (3) The solvents include benzene solvents and alkane-ketone solvents, preferably Tol or NMP.
[0017] In an optional embodiment, S7: Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1, solvent, palladium on carbon, and hydrogen are mixed and reacted; Preferably, the reaction conditions of S7 satisfy at least one of the following requirements: (1) The molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 to palladium on carbon is 1:(0.08-0.12). (2) The reaction temperature is 10-20℃; (3) The solvent includes furan solvents, ester solvents or amide solvents, preferably at least one of tetrahydrofuran, ethyl acetate, N,N-dimethylformamide and N,N-dimethylacetamide.
[0018] The present invention has the following beneficial effects: The embodiments of the present invention can synthesize the key fragments – sequences 25-28 – of Petrelintide (ZP8396) via liquid-phase synthesis, and can achieve production scale-up. This not only solves the problems of low coupling efficiency and easy racemization, but also provides the possibility of reducing synthesis steps and waste emissions in solid-phase peptide synthesis, and can also improve peptide purity and reduce purification difficulty. Attached Figure Description
[0019] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.
[0020] Figure 1 The NMR spectrum of Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OH provided in Embodiment 1 of the present invention; Figure 2 The mass spectrum of Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OH provided in Example 1 of this invention. Detailed Implementation
[0021] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.
[0022] In a first aspect, the present invention provides a method for synthesizing a polypeptide fragment in a ZP8396 polypeptide compound, wherein the polypeptide fragment in the ZP8396 polypeptide compound is a polypeptide with sequences 25-28. The specific synthetic route is as follows:
[0023]
[0024] Specific synthesis methods include: S1: RN-Me-Ile-OH and Leu-OR1 salt are condensed to form RN-Me-Ile-Leu-OR1. Specifically, the RN-Me-Ile-OH, the Leu-OR1 hydrochloride, a condensing agent, and a base are mixed and reacted. Wherein, R is any one of Fmoc, Boc, Cbz, and Alloc, preferably Fmoc; the condensing agent is selected from at least one of HOBT, TBTU, and HATU; the base includes nitrogen-containing organic compounds, such as, but not limited to, N-methylimidazole; the molar ratio of RN-Me-Ile-OH to the Leu-OR1 hydrochloride is 1:(1.1-1.3); for example, any value between 1:1.1, 1:1.2, 1:1.3, or 1:(1.1-1.3). The ratio of RN-Me-Ile-OH to the condensing agent is 1:(2-2.5); for example, any value between 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, or 1:(2-2.5). The ratio of RN-Me-Ile-OH to the base is 1:(2-2.5); for example, any value between 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, or 1:(2-2.5).
[0025] S2: Remove R from RN-Me-Ile-Leu-OR1 to form HN-Me-Ile-Leu-OR1, where R1 is any one of Bn, Me, Et, tBu, OMB, and PMB, preferably Bn. Specifically, RN-Me-Ile-Leu-OR1, a deprotecting agent, and a solvent are mixed to remove R. The deprotecting agent includes bicyclic amidine organic strong bases, such as, but not limited to, DBU. The solvent includes furan derivatives or amides, such as, but not limited to, DMF or THF; the reaction temperature is 0-10°C; for example, any value between 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, or 0-10°C. The molar ratio of RN-Me-Ile-Leu-OR1 to the deprotecting agent is 1:(0.8-1.2).
[0026] S3: Fmoc-Ala-OH is condensed with HN-Me-Ile-Leu-OR1 to form Fmoc-Ala-N-Me-Ile-Leu-OR1. Specifically, Fmoc-Ala-OH, HN-Me-Ile-Leu-OR1, a condensing agent, and a solvent are mixed and reacted. The condensing agent includes EEDQ or PyAOP; the solvent includes furan derivatives or amides, such as, but not limited to, DMF or THF; the molar ratio of Fmoc-Ala-OH to HN-Me-Ile-Leu-OR1 is 1:(1-1.5); the reaction temperature is 0-5℃, and the reaction time is 2-30 h.
[0027] S4: Hydrogenation removal of R1 from Fmoc-Ala-N-Me-Ile-Leu-OR1; specifically, hydrogenation removal of R1 from Fmoc-Ala-N-Me-Ile-Leu-OR1 using palladium on carbon. The mass ratio of Fmoc-Ala-N-Me-Ile-Leu-OR1 to palladium on carbon is (8-12):1; for example, any value between 8:1, 9:1, 10:1, 11:1, 12:1, or (8-12):1. The reaction temperature is 10-20℃; for example, any value between 10℃, 11℃, 12℃, 13℃, 14℃, 15℃, 16℃, 17℃, 18℃, 19℃, 20℃, or 10-20℃. The solvent used for hydrogenation removal includes furan-based solvents or ester solvents, preferably tetrahydrofuran or ethyl acetate.
[0028] S5; Fmoc-Ala-N-Me-Ile-Leu-OH is coupled with H-Ser-OR1 salt to form Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1. Specifically, the solvent, Fmoc-Ala-N-Me-Ile-Leu-OH, and condensing agent are mixed at -5 to 0°C. After mixing, the mixture is stirred at 10-20°C, then cooled to -5 to 0°C, followed by the addition of an organic acid, H-Ser-OR1 hydrochloride, solvent, and amine. The mixture is then reacted at 10-20°C. The condensing agent includes at least one of HOSU, DIC, EDCI, and TBTU; the amine includes DIEA; the molar ratio of Fmoc-Ala-N-Me-Ile-Leu-OH to the H-Ser-OR1 salt is 1:(1.1-1.3).
[0029] S6: Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 undergoes a ring-closure reaction under catalyst catalysis to form Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1. Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 is then formed using 2-methoxypropylene under PPTS catalysis. Specifically, the solvent, Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1, and PPTS are mixed, and then 2-methoxypropylene is added in batches under an inert gas atmosphere. The solvent includes benzene-based solvents and alkane-ketone solvents, preferably Tol or NMP; the molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 to PPTS is 1:(0.08-0.12); the molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 to 2-methoxypropylene is 1:(6-12).
[0030] S7: Remove R1 from Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 to form Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OH (i.e., sequences 25-28); mix Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1, solvent, palladium on carbon, and hydrogen for reaction. The solvent includes furan solvents, ester solvents, or amide solvents, preferably at least one of tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, and N,N-dimethylacetamide; the reaction temperature is 10-20℃; the molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 to palladium on carbon is 1:(0.08-0.12).
[0031] The features and performance of the present invention will be further described in detail below with reference to embodiments.
[0032] Example 1 This invention provides a method for synthesizing Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OH, which is carried out according to the following synthetic route:
[0033]
[0034] The specific synthesis steps are as follows: S1: Add DMF (1.5 L) to a 3000 mL three-necked flask, start stirring, and add Fmoc-N-Me-Ile-OH (300 g, 1.0 eq.). Under nitrogen protection, cool to below 0°C in an ice-salt bath. Then add HOBT (110.32 g, 1.0 eq.) and TBTU (314.58 g, 1.2 eq.) to the system sequentially. Next, add NMI (100.55 g, 1.5 eq.) dropwise to the system and stir for 0.5 h after each addition. Then add H-Leu-OBn•HCl (244.11 g, 1.1 eq.) to the system, followed by NMI (67.03 g, 1.0 eq.) dropwise. After the addition is complete, remove the ice bath and warm the system in a water bath to 15°C for 3 h.
[0035] After the TLC showed that the reactants had reacted completely, EA (1.5 L) was added to the reaction system. Then, 5% sodium bicarbonate solution (1.5 L) was slowly added under ice bath conditions (internal temperature below 10 °C). The organic phase was retained, and the aqueous phase was back-extracted once with EA (1 L). The organic phases were combined and washed once with 5% sodium bicarbonate solution (1.5 L). The liquid was separated, and the organic phase was taken. The organic phase was washed again with saturated brine (1.5 L). After drying with 450 g of anhydrous sodium sulfate, the solution was concentrated under reduced pressure using a diaphragm pump at 45 °C to obtain 460 g of colorless oily substance with a yield of 92% and a purity of 93%.
[0036] S2: Add THF (1.3 L) and Fmoc-N-Me-Ile-Leu-OBn (460 g, 1.0 eq.) to a 5 L three-necked flask; add DBU (122.71 g, 1.0 eq.) under ice bath temperature control at 0℃, and keep warm to 0℃ while stirring for 10 min.
[0037] After the TLC showed that the reactants had reacted completely, PE (1000 mL) was added to the system, followed by 1N hydrochloric acid (1800 mL) to adjust the pH to 3-4. The mixture was separated, and the aqueous phase was extracted three times with PE (900 mL):EA (300 mL) in a 3:1 ratio to remove impurities. The aqueous phase was then retained. 5% sodium bicarbonate aqueous solution (500 mL) was added to the aqueous phase to adjust the pH to 7-8, followed by EA (1000 mL). The product was extracted twice, and the organic phase was retained. 5% sodium bicarbonate aqueous solution (500 mL) was added to the organic phase for washing once. The organic phase was allowed to stand and separated. The organic phase was washed once with saturated brine (1000 mL) and allowed to stand. Anhydrous sodium sulfate (500 g) was added to the organic phase, stirred, and dried. The filtrate was collected and concentrated under reduced pressure to obtain 280 g of a pale yellow oily substance with a purity of 92.36% and a yield of 100%.
[0038] S3: Add THF (1050 mL) to a 3 L three-necked flask, start stirring, and then add Fmoc-Ala-OH (210 g, 1.0 eq.), HN-Me-Ile-Leu-OBn (266.64 g, 1.2 eq.) and EEDQ (189.21 g, 1.2 eq.) in sequence. Heat the reaction system in an oil bath at 25 °C for 16 h.
[0039] TLC showed that the reaction of the raw materials was complete. The reaction solution was diluted and dissolved with EA (1000 mL), and water (1600 mL) was added and stirred to disperse. The pH was adjusted to 7-8 with DIEA (210 g) to wash the carboxylic acid raw materials. After stirring for 10 min, the mixture was allowed to stand and separated. 1 N hydrochloric acid aqueous solution (1800 mL) was added to the organic phase to adjust the pH to 3-5 to wash the residual organic base and condensation agent byproduct quinoline. After stirring for 10 min, the mixture was allowed to stand and separated. The organic phase was washed once with saturated brine (1000 mL) and then dried with anhydrous sodium sulfate (800 g). The organic phase was concentrated under reduced pressure to obtain 650 g of yellow oily crude product. The crude product was further purified by column chromatography. The column-purified product was concentrated by vacuum distillation at 45°C to obtain 309 g of colorless oily product with a purity of 96.01%.
[0040] S4: After nitrogen purging three times, add THF (400 mL) to a 2000 mL single-necked flask, turn on magnetic stirring, then add Fmoc-Ala-N-Me-Ile-Leu-OBn (80 g) and Pd / C (8 g), and after hydrogen purging three times, react at 15 °C for 6 h.
[0041] TLC showed that the reaction of the raw materials was complete. The mixture was filtered through a diatomaceous earth filter (50 g), and the filter cake was washed with THF (80 mL). Stirring was started, and water (400 mL) and petroleum ether (400 mL) were added to the filtrate. Then, DIEA (22.4 g) was added to adjust the pH to 7-8. The mixture was allowed to stand and separated. Impurities were extracted once with petroleum ether (300 mL), and the aqueous phase was retained. Stirring was started, and ethyl acetate (400 mL) was added to the aqueous phase. The pH was adjusted to 3-4 with 0.5 N HCl (200 mL). The mixture was allowed to stand and separated. The organic phase was washed once with saturated brine (300 mL), and the organic phase was retained. The organic phase was dried with anhydrous sodium sulfate (150 g) and stirred for 10 min before filtration. The filtrate was concentrated under reduced pressure using a diaphragm pump at 45°C to 56 g of foamy solid. After purification by column chromatography, 44 g of foamy solid was obtained with a purity of 99.21% and a yield of 64%.
[0042] S5: Add THF (480 mL), Fmoc-Ala-N-Me-Ile-Leu-OH (164 g, 1.0 eq.), and HOSU (37.64 g, 1.1 eq.) sequentially to a 2000 mL three-necked flask purged with nitrogen three times, and stir for 10 min until dissolved; keep the temperature at 0 °C, and add DIC (43.14 g, 1.15 eq.) dropwise to the above reaction system until the addition is complete, and then warm the system in a water bath at 15 °C and stir overnight; filter to remove the byproduct DIU, cool the filtrate to 0 °C, add AcOH (8.93 g, 0.5 eq.), and stir for 0.5 h; add H-Ser-OBn•HCl (79.20 g, 1.15 eq.), THF (320 mL, 2 V), and DIEA (76.84 g, 2.0 eq.) to the system, and allow it to warm naturally to 15 °C for 3 h.
[0043] TLC showed that the reaction of the raw materials was complete. EA (1600 mL) was added to the filtrate, and the mixture was cooled to below 10°C in an ice-water bath. The reaction was then quenched and terminated by slowly adding 800 mL of 12.5% sodium chloride aqueous solution while maintaining the temperature below 20°C. The reaction solution was transferred to a separatory funnel, allowed to stand, and separated, retaining the organic phase. The organic phase was dried with anhydrous sodium sulfate (500 g) and filtered. The organic phase was concentrated to dryness at 45°C using a water pump, yielding 260 g of a yellow foamy solid. After purification by column chromatography, 113 g of product was obtained with a purity of 94.13% and a yield of 61%.
[0044] S6: Dissolve Fmoc-Ala-N-Me-Ile-Leu-Ser-OBn (160 g, 1.0 eq.) in Tol (800 mL), then add PPTS (5.52 g, 0.1 eq.). Under N2 conditions, slowly add 2-methoxypropylene (47.49 g, 3.0 eq.) using a constant pressure dropping funnel. After reacting for 1 h, add another 2-methoxypropylene (47.49 g, 3.0 eq.) to the system, heat to 60 °C, and react for another 2 h. Then add more 2-methoxypropylene (47.49 g, 3.0 eq.).
[0045] TLC showed that the reaction of the raw materials was complete. 800 mL of 5% sodium bicarbonate solution was added, and the mixture was separated. The organic phase was dried with 800 mL of saturated saline solution and 200 g of anhydrous sodium sulfate. After concentration, it was purified by column chromatography to obtain 120 g of white foamy solid with a purity of 86.45% and a yield of 71%.
[0046] S7: Nitrogen was purged three times, THF (600 mL) was added to a 1000 mL single-necked flask, magnetic stirring was turned on, and then Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OBn (120 g, 1.0 eq.) and Pd / C (12 g, 0.1 w / w) were added. Hydrogen was purged three times, and the reaction was carried out at 15 °C for 5 h under H2 conditions.
[0047] TLC showed that the reaction of the raw materials was complete. After filtering the system with palladium on carbon using diatomaceous earth, 600 mL of PE and 600 mL of water were added to the system. Then, 15 mL of DIEA was added to adjust the pH to 7-8, and the aqueous phase was collected. Two 600 mL solutions of PE were added to extract and wash away small polar impurities, and the aqueous phase was collected again. 800 mL of EA was added, followed by 50 mL of 0.5 M HCl to adjust the pH to 3-4, and the organic phase was collected. The organic phase was concentrated and evaporated to dryness to obtain 24 g of a white solid product with a purity of 98% and a yield of 22%. The NMR spectrum of this product is shown below. Figure 1 See mass spectrum Figure 2 .
[0048] Process Research 1 Referring to step S1 of the synthesis method in Example 1, using Fmoc-N-Me-Ile-OH and H-Leu-OBn•HCl as standard substrates, the types of reaction condensing agents were studied without changing the temperature and reaction time. The results are shown in Table 1.
[0049] Table 1 Test Results
[0050] Process Research 2 Following step S2 of the synthesis method in Example 1, using Fmoc-N-Me-Ile-Leu-OBn and DBU as standard substrates, the solvent in the reaction was studied without changing the temperature, and the results are shown in Table 2.
[0051] Table 2 Test Results
[0052] Process Research 3 Referring to step S3 of the synthesis method in Example 1, the types of reaction condensing agents were studied using Fmoc-Ala-OH and HN-Me-Ile-Leu-OBn without changing the temperature and reaction time. The results are shown in Table 3.
[0053] Table 3 Test Results
[0054] Process Research 4 Following step S4 of the synthesis method in Example 1, using Fmoc-Ala-N-Me-Ile-Leu-OBn, wet palladium on carbon, and hydrogen as standard substrates, the solvent in the reaction was studied without changing the temperature, and the results are shown in Table 4.
[0055] Table 4 Test Results
[0056] Process Research 5 Referring to step S5 of the synthesis method in Example 1, the types of reaction condensing agents were studied using Fmoc-Ala-N-Me-Ile-Leu-OH and H-Ser-OBn•HCl, without changing the temperature and reaction time. The results are shown in Table 5.
[0057] Table 5 Test Results
[0058] Process Research 6 Following step S6 of the synthesis method in Example 1, using Fmoc-Ala-N-Me-Ile-Leu-Ser-OBn, 2-methoxypropylene, and PPTS as standard substrates, the solvent in the reaction was studied without changing the temperature, and the results are shown in Table 6.
[0059] Table 6 Test Results
[0060] Process Research 7 Referring to step S7 of the synthesis method in Example 1, using Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OBn, wet palladium on carbon, and hydrogen as standard substrates, the solvent in the reaction was studied without changing the temperature, and the results are shown in Table 7.
[0061] Table 7 Test Results
[0062] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A method for synthesizing polypeptide fragments in a ZP8396 polypeptide compound, characterized in that, include: S1: The condensation reaction of RN-Me-Ile-OH and Leu-OR1 salts forms RN-Me-Ile-Leu-OR1; S2: Remove R from RN-Me-Ile-Leu-OR1 to form HN-Me-Ile-Leu-OR1; S3: Fmoc-Ala-OH is condensed with HN-Me-Ile-Leu-OR1 to form Fmoc-Ala-N-Me-Ile-Leu-OR1; S4: Remove R1 from Fmoc-Ala-N-Me-Ile-Leu-OR1 to form Fmoc-Ala-N-Me-Ile-Leu-OH; S5; Fmoc-Ala-N-Me-Ile-Leu-OH is coupled with H-Ser-OR1 salt to form Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1; S6: Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 undergoes a ring-closing reaction under the catalysis of a catalyst to form Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1; S7: Remove R1 from Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 to form Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-OH; Where R is any one of Fmoc, Boc, Cbz and Alloc, and R1 is any one of Bn, Me, Et, tBu, OMB and PMB.
2. The synthesis method according to claim 1, characterized in that, R stands for Fmoc, and R1 stands for Bn.
3. The synthesis method according to claim 1, characterized in that, S1: The RN-Me-Ile-OH, the Leu-OR1 hydrochloride, the condensing agent, and the base are mixed and reacted. Preferably, the reaction conditions of S1 satisfy at least one of the following requirements: (1) The molar ratio of RN-Me-Ile-OH to Leu-OR1 hydrochloride is 1:(1.1-1.3). (2) The condensing agent is selected from at least one of HOBT, TBTU and HATU; (3) The ratio of RN-Me-Ile-OH to the condensing agent is 1:(2-2.5); (4) The ratio of RN-Me-Ile-OH to the base is 1:(2-2.5); (5) The base includes a nitrogen-containing organic compound, preferably N-methylimidazole; (6) The reaction temperature is 0-5℃ and the reaction time is 2-6h.
4. The synthesis method according to claim 1, characterized in that, S2: Remove R by mixing RN-Me-Ile-Leu-OR1, deprotectant, and solvent; Preferably, the reaction conditions for S2 satisfy at least one of the following requirements: (1) The reaction temperature is 0-10℃; (2) The deprotecting agent includes a bicyclic amidine organic strong base, preferably DBU; (3) The solvent includes furan derivatives or amides, preferably DMF or THF; (4) The molar ratio of RN-Me-Ile-Leu-OR1 to the deprotecting agent is 1: (0.8-1.2).
5. The synthesis method according to claim 1, characterized in that, S3: Mix Fmoc-Ala-OH, the HN-Me-Ile-Leu-OR1, the condensing agent and the solvent to carry out the reaction; Preferably, the reaction conditions for S3 satisfy at least one of the following requirements: (1) The molar ratio of Fmoc-Ala-OH and HN-Me-Ile-Leu-OR1 is 1:(1-1.5). (2) The condensing agent includes EEDQ or PyAOP; The solvent includes furan derivatives or amide substances, preferably DMF or THF; (3) The reaction temperature is 0-5℃ and the reaction time is 2-30h.
6. The synthesis method according to claim 1, characterized in that, S4: Hydrogenation to remove R1 from Fmoc-Ala-N-Me-Ile-Leu-OR1; Preferably, palladium carbon hydrogenation is used to remove R1 from the Fmoc-Ala-N-Me-Ile-Leu-OR1; Preferably, the reaction conditions for S4 satisfy at least one of the following requirements: (1) The mass ratio of Fmoc-Ala-N-Me-Ile-Leu-OR1 to palladium on carbon is (8-12):1; (2) The reaction temperature is 10-20℃; (3) The solvents used for hydrogenation removal include furan solvents or ester solvents, preferably tetrahydrofuran or ethyl acetate.
7. The synthesis method according to claim 1, characterized in that, S5: Mix the solvent, Fmoc-Ala-N-Me-Ile-Leu-OH and condensing agent at -5 to 0℃. After mixing, stir at 10-20℃, then cool to -5 to 0℃, add organic acid, then add H-Ser-OR1 hydrochloride, solvent and amine, and react at 10-20℃. Preferably, the reaction conditions of S5 satisfy at least one of the following requirements: (1) The molar ratio of the Fmoc-Ala-N-Me-Ile-Leu-OH salt to the H-Ser-OR1 salt is 1:(1.1-1.3); (2) The condensing agent includes at least one of HOSU, DIC, EDCI and TBTU; (3) The amines include DIEA.
8. The synthesis method according to claim 1, characterized in that, S6: Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 is formed by cyclization reaction of 2-methoxypropylene under the catalysis of PPTS.
9. The synthesis method according to claim 1, characterized in that, S6: Mix the solvent, Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 and PPTS, and then add 2-methoxypropylene in batches under an inert gas atmosphere; Preferably, (1) the molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 to PPTS is 1:(0.08-0.12). (2) The molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser-OR1 to 2-methoxypropylene is 1:(6-12). (3) The solvents include benzene solvents and alkane-ketone solvents, preferably Tol or NMP.
10. The synthesis method according to claim 1, characterized in that, S7: Mix Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1, solvent, palladium on carbon, and hydrogen to carry out the reaction; Preferably, the reaction conditions of S7 satisfy at least one of the following requirements: (1) The molar ratio of Fmoc-Ala-N-Me-Ile-Leu-Ser(Psi(Me,Me)Pro)-R1 to palladium on carbon is 1:(0.08-0.12). (2) The reaction temperature is 10-20℃; (3) The solvent includes furan solvents, ester solvents or amide solvents, preferably at least one of tetrahydrofuran, ethyl acetate, N,N-dimethylformamide and N,N-dimethylacetamide.
